Market Buzz: EXACT Sciences Corporation (NASDAQ:EXAS), Gilead Sciences Inc. (NASDAQ:GILD), Celgene Corporation (NASDAQ:CELG)

Lakeway, NY — (US MARKET BUZZ) — 12/17/2014—, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on EXACT Sciences Corporation (NASDAQ:EXAS), Gilead Sciences Inc. (NASDAQ:GILD), Celgene Corporation (NASDAQ:CELG).

EXACT Sciences Corporation (NASDAQ:EXAS)’s shares declined 5.72% to $25.51. The company on Dec. 16 announced the pricing of the public offering of 4,000,000 common shares previously sold to Jefferies LLC and Robert W. Baird & Co. Incorporated, as underwriters of the offering. The common shares will be sold at a public offering price of $25.75 per share. The Company has also granted the underwriters an option to purchase up to 600,000 additional shares. The offering is expected to close on or about December 19, 2014, subject to customary closing conditions.

Should Investors Buy EXAS After The Recent Development? Find Out Here

Gilead Sciences Inc. (NASDAQ:GILD)’s shares declined 0.63% to $105.17. The company on Dec. 15 announced that Philippe C. Bishop, MD, will join the company as Senior Vice President, Hematology and Oncology Therapeutics. In this position, Dr. Bishop will report to John McHutchison, MD, Executive Vice President, Clinical Research and will have responsibility for Gilead’s programs in oncology. Dr. Bishop will also join Gilead’s Executive Committee.

Is GILD Going To Rise or Fall After Today’s Price Action? Find Out Here

Additionally, the company on Dec. 8 announced long-term follow-up results from the registration studies further describing the duration of response, progression-free survival (PFS) and safety profile for Zydelig® (idelalisib) in relapsed patients with chronic lymphocytic leukemia (CLL) and two types of indolent non-Hodgkin lymphoma (iNHL).

Celgene Corporation (NASDAQ:CELG)’s shares declined 1.05% to $111.08. The company on Dec. 9 announced that data were presented from a phase 1b/2 study of ISTODAX® (romidepsin) combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with peripheral t-cell lymphoma were presented during the 56th American Society of Hematology annual meeting. In the phase Ib and phase II portions of this study, presented by Jehan Dupuis, M.D. (from the Lymphoma Study Association or LYSA), a total of 37 patients were treated with romidepsin at varying doses plus CHOP. Based on results from phase I (n=18), the recommended dose of romidepsin for the phase II portion was 12 mg/m2 (n= 19).

Can Traders Buy CELG After The Solid Rally? Get Free Trend Analysis Here

About is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.

Jean Jadhon career began at ABC 6 News. She worked as a production assistant, intern, and finally a reporter. Then, her husband's job took her to Omaha, NE, where she spent a year working as the mreporter. Having grown up in Minnesota, and graduating college in Rochester. She has a degree in Mass Communications, and reported, anchored and produced for her campus news show. She was also the managing editor of the student newspaper. Jean Jadhon says she is excited to be back, and loves the people of Southeast Minnesota. When she is not working, she likes to spend time at home with her husband Damian, and two kids; Aiden and Lucy.